» Articles » PMID: 32790658

Notes from the Field: Seroprevalence Estimates of SARS-CoV-2 Infection in Convenience Sample - Oregon, May 11-June 15, 2020

Overview
Date 2020 Aug 14
PMID 32790658
Citations 20
Authors
Affiliations
Soon will be listed here.
Citing Articles

Pediatric SARS-CoV-2 Seroprevalence, Oregon, USA, November 1, 2020-June 30, 2022.

Falender R, Mitchell P, Guzman-Cottrill J, Cieslak P, Sutton M Emerg Infect Dis. 2023; 29(8):1672-1675.

PMID: 37486347 PMC: 10370852. DOI: 10.3201/eid2908.230471.


Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.

Metzger C, Leroy T, Bochnakian A, Jeulin H, Gegout-Petit A, Legrand K PLoS One. 2023; 18(4):e0269104.

PMID: 37075077 PMC: 10118383. DOI: 10.1371/journal.pone.0269104.


Geographically skewed recruitment and COVID-19 seroprevalence estimates: a cross-sectional serosurveillance study and mathematical modelling analysis.

Brown T, de Salazar Munoz P, Bhatia A, Bunda B, Williams E, Bor D BMJ Open. 2023; 13(3):e061840.

PMID: 36882240 PMC: 10008195. DOI: 10.1136/bmjopen-2022-061840.


Leveraging CTSA hubs for rapid, large-scale, high-impact research: A case study during a global public health emergency.

Croker J, Valenti S, Baus H, Ford E, Mathias D, Yasko L J Clin Transl Sci. 2023; 7(1):e13.

PMID: 36755544 PMC: 9879899. DOI: 10.1017/cts.2022.484.


The Longitudinal Analysis on the Anti-SARS-CoV-2 Antibodies among Healthcare Workers in Poland-Before and after BNT126b2 mRNA COVID-19 Vaccination.

Lorent D, Nowak R, Luwanski D, Pisarska-Krawczyk M, Figlerowicz M, Zmora P Vaccines (Basel). 2022; 10(10).

PMID: 36298441 PMC: 9607217. DOI: 10.3390/vaccines10101576.


References
1.
Bryan A, Pepper G, Wener M, Fink S, Morishima C, Chaudhary A . Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol. 2020; 58(8). PMC: 7383515. DOI: 10.1128/JCM.00941-20. View

2.
Havers F, Reed C, Lim T, Montgomery J, Klena J, Hall A . Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020; . DOI: 10.1001/jamainternmed.2020.4130. View

3.
Menachemi N, Yiannoutsos C, Dixon B, Duszynski T, Fadel W, Wools-Kaloustian K . Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample - Indiana, April 25-29, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(29):960-964. PMC: 7377824. DOI: 10.15585/mmwr.mm6929e1. View

4.
Biggs H, Harris J, Breakwell L, Dahlgren F, Abedi G, Szablewski C . Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(29):965-970. PMC: 7377817. DOI: 10.15585/mmwr.mm6929e2. View